CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: Analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma

Akihiro Takeshita, Kaori Shinjo, Nozomi Yamakage, Takaaki Ono, Isao Hirano, Hirotaka Matsui, Kazuyuki Shigeno, Satoki Nakamura, Tadasu Tobita, Masato Maekawa, Kazunori Ohnishi, Yoshikazu Sugimoto, Hitoshi Kiyoi, Tomoki Naoe, Ryuzo Ohno

研究成果: Article

39 引用 (Scopus)

抄録

The effect of CMC-544, a calicheamicin-conjugated anti-CD22 monoclonal antibody, was analysed in relation to CD22 and P-glycoprotein (P-gp) in B-cell chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL) in vitro. The cell lines used were CD22-positive parental Daudi and Raji, and their P-gp positive sublines, Daudi/MDR and Raji/MDR. Cells obtained from 19 patients with B-cell CLL or NHL were also used. The effect of CMC-544 was analysed by viable cell count, morphology, annexin-V staining, and cell cycle distribution. A dose-dependent, selective cytotoxic effect of CMC-544 was observed in cell lines that expressed CD22. CMC-544 was not effective on Daudi/MDR and Raji/MDR cells compared with their parental cells. The MDR modifiers, PSC833 and MS209, restored the cytotoxic effect of CMC-544 in P-gp-expressing sublines. In clinical samples, the cytotoxic effect of CMC-544 was inversely related to the amount of P-gp (P = 0·003), and to intracellular rhodamine-123 accumulation (P < 0·001). On the other hand, the effect positively correlated with the amount of CD22 (P = 0·010). The effect of CMC-544 depends on the levels of CD22 and P-gp. Our findings will help to predict the clinical effectiveness of this drug on these B-cell malignancies, suggesting a beneficial effect with combined use of CMC-544 and MDR modifiers.

元の言語English
ページ(範囲)34-43
ページ数10
ジャーナルBritish Journal of Haematology
146
発行部数1
DOI
出版物ステータスPublished - 2009 7

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
P-Glycoprotein
Cell Line
Non-Hodgkin's Lymphoma
Rhodamine 123
Inotuzumab Ozogamicin
Annexin A5
Cell Cycle
B-Lymphocytes
Cell Count
Monoclonal Antibodies
Staining and Labeling
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hematology

これを引用

CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells : Analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. / Takeshita, Akihiro; Shinjo, Kaori; Yamakage, Nozomi; Ono, Takaaki; Hirano, Isao; Matsui, Hirotaka; Shigeno, Kazuyuki; Nakamura, Satoki; Tobita, Tadasu; Maekawa, Masato; Ohnishi, Kazunori; Sugimoto, Yoshikazu; Kiyoi, Hitoshi; Naoe, Tomoki; Ohno, Ryuzo.

:: British Journal of Haematology, 巻 146, 番号 1, 07.2009, p. 34-43.

研究成果: Article

Takeshita, A, Shinjo, K, Yamakage, N, Ono, T, Hirano, I, Matsui, H, Shigeno, K, Nakamura, S, Tobita, T, Maekawa, M, Ohnishi, K, Sugimoto, Y, Kiyoi, H, Naoe, T & Ohno, R 2009, 'CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: Analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma', British Journal of Haematology, 巻. 146, 番号 1, pp. 34-43. https://doi.org/10.1111/j.1365-2141.2009.07701.x
Takeshita, Akihiro ; Shinjo, Kaori ; Yamakage, Nozomi ; Ono, Takaaki ; Hirano, Isao ; Matsui, Hirotaka ; Shigeno, Kazuyuki ; Nakamura, Satoki ; Tobita, Tadasu ; Maekawa, Masato ; Ohnishi, Kazunori ; Sugimoto, Yoshikazu ; Kiyoi, Hitoshi ; Naoe, Tomoki ; Ohno, Ryuzo. / CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells : Analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. :: British Journal of Haematology. 2009 ; 巻 146, 番号 1. pp. 34-43.
@article{8e71414f32aa4cd8b6fd2e24e9866498,
title = "CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: Analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma",
abstract = "The effect of CMC-544, a calicheamicin-conjugated anti-CD22 monoclonal antibody, was analysed in relation to CD22 and P-glycoprotein (P-gp) in B-cell chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL) in vitro. The cell lines used were CD22-positive parental Daudi and Raji, and their P-gp positive sublines, Daudi/MDR and Raji/MDR. Cells obtained from 19 patients with B-cell CLL or NHL were also used. The effect of CMC-544 was analysed by viable cell count, morphology, annexin-V staining, and cell cycle distribution. A dose-dependent, selective cytotoxic effect of CMC-544 was observed in cell lines that expressed CD22. CMC-544 was not effective on Daudi/MDR and Raji/MDR cells compared with their parental cells. The MDR modifiers, PSC833 and MS209, restored the cytotoxic effect of CMC-544 in P-gp-expressing sublines. In clinical samples, the cytotoxic effect of CMC-544 was inversely related to the amount of P-gp (P = 0·003), and to intracellular rhodamine-123 accumulation (P < 0·001). On the other hand, the effect positively correlated with the amount of CD22 (P = 0·010). The effect of CMC-544 depends on the levels of CD22 and P-gp. Our findings will help to predict the clinical effectiveness of this drug on these B-cell malignancies, suggesting a beneficial effect with combined use of CMC-544 and MDR modifiers.",
keywords = "Calicheamicin, CD22, CMC-544, Monoclonal antibody, P-glycoprotein",
author = "Akihiro Takeshita and Kaori Shinjo and Nozomi Yamakage and Takaaki Ono and Isao Hirano and Hirotaka Matsui and Kazuyuki Shigeno and Satoki Nakamura and Tadasu Tobita and Masato Maekawa and Kazunori Ohnishi and Yoshikazu Sugimoto and Hitoshi Kiyoi and Tomoki Naoe and Ryuzo Ohno",
year = "2009",
month = "7",
doi = "10.1111/j.1365-2141.2009.07701.x",
language = "English",
volume = "146",
pages = "34--43",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells

T2 - Analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma

AU - Takeshita, Akihiro

AU - Shinjo, Kaori

AU - Yamakage, Nozomi

AU - Ono, Takaaki

AU - Hirano, Isao

AU - Matsui, Hirotaka

AU - Shigeno, Kazuyuki

AU - Nakamura, Satoki

AU - Tobita, Tadasu

AU - Maekawa, Masato

AU - Ohnishi, Kazunori

AU - Sugimoto, Yoshikazu

AU - Kiyoi, Hitoshi

AU - Naoe, Tomoki

AU - Ohno, Ryuzo

PY - 2009/7

Y1 - 2009/7

N2 - The effect of CMC-544, a calicheamicin-conjugated anti-CD22 monoclonal antibody, was analysed in relation to CD22 and P-glycoprotein (P-gp) in B-cell chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL) in vitro. The cell lines used were CD22-positive parental Daudi and Raji, and their P-gp positive sublines, Daudi/MDR and Raji/MDR. Cells obtained from 19 patients with B-cell CLL or NHL were also used. The effect of CMC-544 was analysed by viable cell count, morphology, annexin-V staining, and cell cycle distribution. A dose-dependent, selective cytotoxic effect of CMC-544 was observed in cell lines that expressed CD22. CMC-544 was not effective on Daudi/MDR and Raji/MDR cells compared with their parental cells. The MDR modifiers, PSC833 and MS209, restored the cytotoxic effect of CMC-544 in P-gp-expressing sublines. In clinical samples, the cytotoxic effect of CMC-544 was inversely related to the amount of P-gp (P = 0·003), and to intracellular rhodamine-123 accumulation (P < 0·001). On the other hand, the effect positively correlated with the amount of CD22 (P = 0·010). The effect of CMC-544 depends on the levels of CD22 and P-gp. Our findings will help to predict the clinical effectiveness of this drug on these B-cell malignancies, suggesting a beneficial effect with combined use of CMC-544 and MDR modifiers.

AB - The effect of CMC-544, a calicheamicin-conjugated anti-CD22 monoclonal antibody, was analysed in relation to CD22 and P-glycoprotein (P-gp) in B-cell chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL) in vitro. The cell lines used were CD22-positive parental Daudi and Raji, and their P-gp positive sublines, Daudi/MDR and Raji/MDR. Cells obtained from 19 patients with B-cell CLL or NHL were also used. The effect of CMC-544 was analysed by viable cell count, morphology, annexin-V staining, and cell cycle distribution. A dose-dependent, selective cytotoxic effect of CMC-544 was observed in cell lines that expressed CD22. CMC-544 was not effective on Daudi/MDR and Raji/MDR cells compared with their parental cells. The MDR modifiers, PSC833 and MS209, restored the cytotoxic effect of CMC-544 in P-gp-expressing sublines. In clinical samples, the cytotoxic effect of CMC-544 was inversely related to the amount of P-gp (P = 0·003), and to intracellular rhodamine-123 accumulation (P < 0·001). On the other hand, the effect positively correlated with the amount of CD22 (P = 0·010). The effect of CMC-544 depends on the levels of CD22 and P-gp. Our findings will help to predict the clinical effectiveness of this drug on these B-cell malignancies, suggesting a beneficial effect with combined use of CMC-544 and MDR modifiers.

KW - Calicheamicin

KW - CD22

KW - CMC-544

KW - Monoclonal antibody

KW - P-glycoprotein

UR - http://www.scopus.com/inward/record.url?scp=66949176946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66949176946&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2009.07701.x

DO - 10.1111/j.1365-2141.2009.07701.x

M3 - Article

C2 - 19388933

AN - SCOPUS:66949176946

VL - 146

SP - 34

EP - 43

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -